ICU Medical (NASDAQ:ICUI) Reports Strong Q2 CY2026

Medical device company ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.5% year on year to $551.7 million. Its non-GAAP profit of $2.37 per share was 23.8% above analysts’ consensus estimates.

Is now the time to buy ICU Medical? Find out by accessing our full research report, it’s free.

Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business."

Company Overview

Founded in 1984 and named for its initial focus on intensive care units, ICU Medical (NASDAQ:ICUI) develops and manufactures medical products for infusion therapy, vascular access, and vital care applications used in hospitals and other healthcare settings.

Revenue Growth

A company’s long-term sales performance can indicate its overall quality. Any business can have short-term success, but a top-tier one grows for years. Luckily, ICU Medical’s sales grew at a decent 11.6% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. ICU Medical’s recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 2.5% over the last two years.

This quarter, ICU Medical reported modest year-on-year revenue growth of 1.5% but beat Wall Street’s estimates by 3.5%.

Looking ahead, sell-side analysts expect revenue to grow 3.3% over the next 12 months. Although this projection indicates its newer products and services will fuel better top-line performance, it is still below average for the sector.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.

Adjusted Operating Margin

Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.

ICU Medical has done a decent job managing its cost base over the last five years. The company has produced an average adjusted operating margin of 13.2%, higher than the broader healthcare sector.

Looking at the trend in its profitability, ICU Medical’s adjusted operating margin rose by 1.3 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company’s margin has increased by 2.6 percentage points on a two-year basis.

In Q2, ICU Medical generated an adjusted operating margin profit margin of 9.2%, down 5 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.

ICU Medical’s EPS grew at an unimpressive 2.9% compounded annual growth rate over the last five years, lower than its 11.6% annualized revenue growth. However, its adjusted operating margin actually improved during this time, telling us that non-fundamental factors such as interest expenses and taxes affected its ultimate earnings.

We can take a deeper look into ICU Medical’s earnings to better understand the drivers of its performance. A five-year view shows ICU Medical has diluted its shareholders, growing its share count by 15.4%. This dilution overshadowed its increased operational efficiency and has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q2, ICU Medical reported adjusted EPS of $2.37, up from $2.10 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects ICU Medical’s full-year EPS to grow 3.8% from $8.28 to $8.60.

Key Takeaways from ICU Medical’s Q2 Results

We were impressed by how significantly ICU Medical blew past analysts’ full-year EPS guidance expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. Zooming out, we think this was a solid print. The stock traded up 1.4% to $168.02 immediately after reporting.

Indeed, ICU Medical had a rock-solid quarterly earnings result, but is this stock a good investment here? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).